Medical device manufacturer Boston Scientific has received US Food and Drug Administration (FDA) and CE mark approval for its AngioJet ZelanteDVT thrombectomy catheter to treat deep vein thrombosis (DVT) in large-diameter upper and lower limb peripheral veins.
DVT occurs when a blood clot or thrombus forms in one or more of the deep veins, most frequently in the legs.
ZelanteDVT catheter was developed to effectively remove large venous clot burdens and facilitate rapid restoration of blood flow.
Boston Scientific peripheral interventions president Jeff Mirviss said: "The new features of the ZelanteDVT catheter represent our focus on improving procedural efficiencies and reducing the economic burden associated with this challenging condition.
"With this addition to our AngioJet portfolio, we are further evolving the current suite of life-changing therapeutic options available to physicians and their patients with deep vein thrombosis."
The company has developed ZelanteDVT Thrombectomy Set to be used with the AngioJet Ultra Console to break apart and remove thrombus, including DVT, from iliofemoral and lower extremity veins greater than or equal to 6.0mm in diameter, and upper extremity peripheral veins greater than or equal to 6.0mm in diameter.
It can also be used with the AngioJet Power Pulse technique for the controlled and selective infusion of physician specified fluids, including thrombolytic agents, into the peripheral vascular system.
In November this year, the company received CE mark approval for its next generation Watchman FLX left atrial appendage closure (LAAC) device.
The device is a catheter-delivered heart implant developed to close the LAA to avoid the migration of blood clots from the LAA.
Image: AngioJet ZelanteDVT venous thrombectomy catheter. Photo: courtesy of Boston Scientific Corporation.